1 External validation of prognostic and 2 predictive gene signatures in head and ³ neck cancer patients

4

- 5 Erlend I. F. Fossen^{1,2,*}, Mauricio Moreira-Soares¹, Marissa LeBlanc^{1,3}, Arnoldo Frigessi¹,
- 6 Eivind Hovig^{4,5}, Laura Lopez-Perez⁶, Estefanía Estévez-Priego⁶, Liss Hernandez⁶, Maria
- 7 Fernanda Cabrera-Umpierrez⁶, Giuseppe Fico⁶, Ingeborg Tinhofer⁷, Vanessa Sachse⁷,
- 8 Kathrin Scheckenbach⁸, Christophe Le Tourneau⁹, Maud Kamal⁹, Steve Thomas¹⁰, Miranda
- 9 Pring¹⁰, Lisa Licitra^{11,12}, Loris De Cecco^{13§}, Stefano Cavalieri^{11,12§}
- 10
- 11 ¹ Oslo Centre for Biostatistics and Epidemiology, Institute of Basic Medical Sciences,
- 12 University of Oslo, Oslo, Norway
- ²13 CICERO Center for International Climate Research, Oslo, Norway
- ³ Department of Method Development and Analytics, Norwegian Institute of Public Health,
- 15 Oslo, Norway
- ⁴ Centre for Bioinformatics, Department of Informatics, University of Oslo, Oslo, Norway
- ⁵ Department of Tumor biology, Institute for Cancer Research, Oslo University Hospital, 18 0310 Oslo, Norway
- ⁶19 Universidad Politécnica de Madrid-Life Supporting Technologies Research Group, ETSIT, 20 28040 Madrid, Spain
- ⁷21 Department of Radiooncology and Radiotherapy, Translational Radiation Oncology
- 22 Research Laboratory, Charité Universitätsmedizin Berlin, corporate member of Freie
- 23 Universität Berlin and Humboldt Universität zu Berlin, Charitéplatz 1, 10117 Berlin,
- 24 Germany
- ⁸25 Heinrich-Heine-Universität Düsseldorf, Dusseldorf, Germany
- ⁹ Department of Drug Development and Innovation (D3i), Institut Curie, Paris-Saclay
- 27 University, Paris, France
- ¹⁰ 28 Bristol Dental School, University of Bristol, United Kingdom
- ¹¹ Head and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei
-
- 30 Tumori di Milano, via Giacomo Venezian 1, 20133 Milan, Italy $12 \text{ Department of Oncology and Hemato-onology, University of Milan, via Santa Sofia 9/1,}$ 32 20122 Milan, Italy
- ¹³33 Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, via Giacomo
- 34 Venezian 1, 20133 Milan, Italy
- 35
- 36 *Corresponding author, erlend.fossen@cicero.oslo.no
- 37 § Stefano Cavalieri and Loris De Cecco equally contributed as co-last authors.
- 38
- 39

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

It is made available under a CC-BY-NC 4.0 International license.

Abstract

Head and neck squamous cell carcinomas (HNSCC) are aggressive and heterogenous tumors

with a high fatality rate. Many gene signatures (GS) have been developed with both

prognostic and predictive significance. We aimed to externally validate five published GS in

a large European collection of HNSCC patients. Gene expression from 1097 treatment-naïve

HNSCC patients' primary tumors was used to calculate scores for the five GS. Cox

proportional hazard models were used to test the association between both 2-year overall

survival and 2-year disease-free survival and the signature scores. The predictive role of GS

was validated by comparing survival associations in patients receiving specific treatment (i.e.,

radiotherapy, systemic treatment) versus those who did not. We successfully externally

 validated all 5 GS, including two prognostic signatures, one signature as prognostic and predictive of sensitivity to systemic treatment, while signatures for cisplatin-sensitivity and

radiosensitivity were validated as prognostic only.

1. Introduction

Head and neck cancer (HNC) is the $7th$ most common cancer worldwide, with more than 56 890,000 new cases and $450,000$ deaths annually^{1,2}. Head and neck squamous cell carcinoma (HNSCC) is the most common histological type of HNC, making up 90% of all HNC 58 $\cos^{2,3}$, roughly 4.5% of all global cancer diagnoses and approximately 4.6% of all cancer 59 deaths^{1,2}. Major risk factors for HNSCC are tobacco smoking and alcohol consumption^{1,3}, but human papillomavirus (HPV) infection is also a known risk factor for oropharyngeal 61 cancers^4 .

HNSCCs are a heterogenous group of cancers with malignancies developing at various

64 anatomical sub-sites and with high molecular tumor heterogeneity^{5,6}. This heterogeneity

contributes to differences between patients in terms of treatment response with a need for

66 personalized approaches^{6,7}. In general, HNSCC patients with early disease (stage I-II) have

high cure rates with single modality therapies (either surgery or radiotherapy). Subjects with

 loco-regionally advanced disease (stage III-IVa/b) are treated with multimodal approaches 69 (i.e., various combinations of surgery, radiotherapy and systemic treatment)⁸. Despite optimal

treatments, approximately half of patients develop recurrence within 2 years and half die with

71 disease within 5 years from the diagnosis⁹. Reliable biomarkers and gene signatures (GS) are

72 crucial for developing personalized treatment^{10,11}. GS are sets of genes involved in a

biological process that can provide information about the expected disease outcome

74 (prognostic) and/or the response to a specific treatment (predictive)^{10,11}. Prognostic signatures

provide information about disease prognosis irrespective of therapy. Meanwhile, predictive

signatures inform about how likely a patient is to respond to a specific therapy and can

- therefore enable more personalized treatment plans.
-

Many prognostic GS, calculated from gene expression in treatment-naïve tumors, have been

80 . developed for $HNSCC^{12-16}$. External validation of already published GS is an important step

81 towards incorporating GS in clinical practice¹⁷. In this study, we decided to consider only GS

which were already published, and which were either disease- or treatment-specific. Among

them is a 172-gene signature18 (*172-GS*) that was developed to be prognostic of patient's risk

It is made available under a CC-BY-NC 4.0 International license.

 of relapse in HNSCC patients independently of HPV-status, but was later shown to not be 85 prognostic of overall survival (OS) in HPV-positive patients¹⁹. However, in the same patient population, a specific three-cluster HPV signature²⁰ (*3 clusters HPV*) was developed and 87 externally validated as prognostic of $OS¹⁹$. As for predictive signatures, the 10-gene 88 radiosensitivity index²¹ (*RSI*) is among the most validated pan-cancer GSs for prediction of sensitivity to radiotherapy²². Another pan-cancer predictive signature, in this case predictive of cisplatin-sensitivity23 (*pancancer-cisplatin*), was recently developed, but has not been externally validated in HNSCC patients. Lastly, a signature that classifies HNC patients into 92 six different subtypes/clusters was developed by De Cecco et al^{24} . One of them (*Cl3-hypoxia*) 93 showed hypoxic features and was found to be prognostic^{19,25} and related to response to 94 treatment with anti-EGFR agents (cetuximab and afatinib) $26,27$. Using a large collection of HNSCC patients with available gene expression data, we aimed to externally validate two prognostic gene signatures (*172-GS* and *3 clusters HPV*), two predictive gene signatures (*RSI* and *pancancer-cisplatin*) and one prognostic and predictive GS (*Cl3-hypoxia*). In contrast to earlier studies, we wanted to explicitly test whether the prognostic signatures (*172-GS* and *3 clusters HPV*) are valid independent of HPV-status, and explicitly test if the predictive signatures are predictive of treatment response by comparing if the signature effect is only found in patients with a specific treatment and not in patients without that treatment. We tested these signatures using two survival endpoints, OS and disease-free survival (DFS).

2. Methods

2.1. Ethics statement

 This study was conducted in full accordance with the World Medical Association's Declaration of Helsinki (2013 version). The protocol was ethically approved by the Norwegian Regional Committee for Medical and Health Research Ethics (REK) South-East A under application number 270467. The data is securely stored in the University of Oslo's server for sensitive data (TSD/USIT), adhering to the requirements of GDPR legislation. Access to the data is granted only to authorized collaborators who have been included in the ethical approval. All proprietary studies that contributed data obtained ethical approval from their respective local authorities in Italy, Germany, or France. Copies of these ethical approvals were provided to the principal investigator by the data providers. BD2Decide was approved by the Ethical Committee of the Fondazione IRCCS Istituto Nazionale dei Tumori (Milan, Italy) in 2016 and it has two identifiers: INT65-16 and INT66-16. Biomarker analysis of the ARO 04-01 Def-RCT cohort was approved by the Ethical Committee of the Charité - Universitätsmedizin Berlin (Berlin, Germany) in 2010 (EA2/086/10). Biomarker analysis of 121 the DKTKRO Def-RCT was approved by the Ethical Committee of the Technical University of Dresden (Dresden, Germany) in 2014 (EK200112014).

2.2. Patient selection

 Within a European cooperative research project named SuPerTreat (research grant nr. ERAPERMED2019-281, further details in Funding), we first identified and constructed a

It is made available under a CC-BY-NC 4.0 International license.

It is made available under a CC-BY-NC 4.0 International license.

2.3. Endpoints, clinical variables and data harmonization

 OS, defined as survival time from diagnosis until death of any cause or censoring, was recorded in all studies. DFS, defined as time from diagnosis until cancer recurrence or death of any cause, whichever occurred first, or censoring, was recorded in all but two studies (Table S1). Patients were followed for up to 20 years in the period 1989-2017. Co-primary endpoints were 2-year OS and 2-year DFS.

GSs were considered prognostic if they were associated with general disease prognosis

independently of treatments. We defined a GS as predictive if the prognostic capability was

limited to a population receiving a specific treatment.

 Data harmonization of clinical variables was performed following head and neck ontology 187 (HeNeCOn⁴³) and quality rules defined in BD2Decide study²⁸ (extended in the context of the

SuPerTreat project), to achieve comparable measurements across studies (see [Table 1](#page-22-0) and

Tables S2 and S3 for full list of clinical covariates). Tumor staging at diagnosis was

190 performed according to the 7th edition of the AJCC/UICC staging system⁴². The staging

variable was then classified in two main groups based on disease extension: early disease

(stage I-II) vs. loco-regionally advanced disease (stage III-IVa/b). Human papillomavirus

193 (HPV) infection is a known risk factor for oropharyngeal cancer⁴ and HPV-status was

recorded for tumor tissues of all patients with oropharyngeal cancer, using either HPV

DNA/RNA tests (with DNA PCR or ISH with or without E6/E7 mRNA confirmation, as per

local guidelines) or through p16ink4a immunostaining. Non-oropharyngeal HNSCCs

197 (including oral cavity cancers⁴⁴) were considered HPV-negative in analyses. Systemic treatments were coded in two ways: 1) platinum-based (if carboplatin and/or cisplatin were

part of the agents a patient received) or non-platinum based (primarily cetuximab or

paclitaxel); and 2) cetuximab-based (if cetuximab was part of the agents a patient received) or

non-cetuximab based. Patients not receiving systemic treatments were in both cases coded as

 such.

 Treatments (surgery, radiotherapy and systemic therapy) performed with curative intent were recorded as received or not received. This is potentially problematic since Cox regression survival models assume that covariates are measured at baseline (diagnosis) or require information about the timing of treatment. The use of the received treatment as a proxy for 208 intended treatment (a baseline covariate) may result in immortal time bias⁴⁵. We performed extensive sensitivity analyses to evaluate if our results were sensitive to using received treatment as a covariate (Appendix 1). First, we considered the degree of mortality observed during the period prior to when treatments were initiated. Second, we used an external dataset 212 (Head and Neck $5000^{46,47}$) with similar patient characteristics as SuPerTreat and compared treatment coefficients from Cox models with either intended treatment or received treatment as covariates. Third, we compared treatment coefficients from Cox models with received treatment with models where treatment was considered time-dependent (in a subset of 216 patients where the timing of surgery was known). Fourth, we used a landmark analysis $48,49$ and compared treatment coefficients from a Cox model with received treatment with a landmark model where patients without an event or censoring prior to a landmark time point (corresponding with a time at which all patients started treatment) were followed from the 220 landmark time. Lastly, we used quantitative bias analyses⁵⁰ to compare estimates of received treatments with bias-adjusted estimates of treatments. Based on these sensitivity analyses (Results section [3.3.1\)](#page-10-0), we inferred that our models are robust to violations of the assumptions of the Cox regression models, and therefore used received treatment as a

It is made available under a CC-BY-NC 4.0 International license.

covariate in our survival models. Although gene signatures are tested in interaction with

 treatments, the tumor tissue used to obtain gene signature scores were sampled at diagnosis (prior to treatment).

2.4. Bioinformatics analysis

 Gene expression data was profiled on different platforms depending on the study. Three studies (study IDs: BD2_INT_MI, BD2_UDUS, GSE41613) were profiled on Affymetrix microarrays (platforms GPL23126 and GPL570), one study (GECO110) was profiled on Illumina microarray (platform GPL14951), and two studies (SCANDARE, TCGA) were profiled using Illumina RNA-seq. Within studies, Affymetrix data were quantile-normalized using robust multi-array average (RMA). Illumina microarray data were quantile-normalized. For RNA-seq data, within studies, we first removed very lowly expressed genes, where genes were removed if all samples had < 0.25 counts per million (cpm), corresponding to max 5 reads in the smallest sample and max 22 reads in the largest sample. RNA-seq data were then 238 quantile-normalized using the limma R package⁵¹ (function: voom). We used WGCNA 239 package⁵² (function collapseRows and "maxRowVariance" method) to select the most variable probe in cases when multiple probes mapped to the same EntrezID. Probes and ensemble IDs that mapped to multiple EntrezID were removed. All gene expression data were log2-transformed after the abovementioned normalization. Genes that were missing for 243 all patients in a study were removed when combining datasets. ComBat $53,54$ was used to remove batch effects introduced by systemic non-biological technical errors from combining data from multiple studies with different platforms. The largest proprietary study (ID: 246 BD2 INT MI) was used as reference in ComBat, parametric adjustment was performed, and since there is variability in patient characteristics between studies, we only adjusted for the mean to not remove biological variance between the studies. To avoid bias in downstream 249 analyses⁵⁵, we only included the batches (studies) as covariates in ComBat.

 We calculated 5 gene signature scores for each patient following descriptions given in the original publications (see Table S4 for detailed list of genes and weights per signature). The signatures -GS¹⁸, 3 clusters $HPV^{19,20}$, *pancancer-cisplatin*²³, and *Cl3-hypoxia*²⁴ were 254 calculated as weighed sums using the equation: Gene signature score = $\sum_{i=1}^{n} \beta_i \times Exp_i$, 255 where β_i is the weight of the i-th gene (of n genes) and Exp_i is the gene expression of the i-th 256 gene. The *172-GS* signature was calculated using the hacksig package⁵⁶. The radiosensitivity index (*RSI*) signature is based on the expression of 10 specific genes. *RSI* was calculated as a 258 weighed ranked sum using the equation: $RSI = \sum_{i=1}^{10} \beta_i \times Ranked_Exp_i$, where β_i is the weight of the *i*-th gene and *Ranked_Expi* is the ranked gene expression of the *i*-th gene. For each patient the 10 genes were ranked in ascending order using patient-specific expression data, where the gene with the lowest expression is assigned a value of 1, and the gene with the highest expression is assigned a value of 10.

 Each gene signature was mean-centered and scaled by the standard deviation (SD) within its 265 respective dataset to make the scores easier to interpret (mean = , SD = 1, see Appendix 2

for means and SD on original scale). In our OS dataset, 76% of the *172-GS* signature genes

were present, 46% of the *3 clusters HPV* signature genes were present, all *RSI* genes were

present, 92% of the *pancancer-cisplatin* genes were present, and 94% of the *Cl3-hypoxia*

genes were present. For our DFS dataset, the presence of genes was 80% for the *172-GS*

signature, 57% for the *3 clusters HPV* signature, all *RSI* genes present, 92% for *pancancer-*

It is made available under a CC-BY-NC 4.0 International license.

 cisplatin and 94% for *Cl3-hypoxia* genes (see Appendix 2 for a list of missing genes per gene signature). Any missing genes were missing for all individuals, making regression-based

 imputation not a viable option. Instead, all missing genes were imputed as having zero expression. Note that the scaled signature values do not change if we instead were to impute

with another constant (e.g., imputing the overall mean expression).

2.5. Statistical analyses

- 278 All statistical analyses were performed in R Statistical Software⁵⁷ (v4.1.3).
-

2.5.1. Handling of missing clinical covariates

 There were missing data in several categorical variables: smoking status, tumor stage and received treatments (i.e., surgery, systemic therapy and radiotherapy). The missingness was largely structural, resulting from some variables not being measured in some of the studies, 284 and therefore regression-based imputation of missing data was not a viable option⁵⁸. Instead, we used a missing indicator where missing values were coded as belonging to a "missing" category (see [Table 1](#page-22-0) for amounts of missingness).

2.5.2. Clinical base models

 Clinical base models, i.e., those not including the gene expression data, were built as benchmark models for models which included gene signatures as covariates. Four Cox proportional hazard models were fit with either 2-year OS or 2-year DFS as endpoints. Two models were fit with the same data used to test signatures not related to sensitivity to systemic treatment (*172-GS*, *3 clusters HPV* and *RSI*) and two models were fit with the same data used to test signatures related to sensitivity to platinum-based or cetuximab-based treatments (*pancancer-cisplatin* and *Cl3-hypoxia*, respectively). In all models, age, sex, tumor region and HPV-status, smoking status, undergone surgery (yes/no), received radiotherapy (yes/no), and study ID were used as covariates. In models testing signatures not related to systemic treatment, disease extension (early stage, locoregionally advanced) and received systemic therapy (yes/no) were also used as covariates. In models testing signatures related to systemic treatment, TNM stage and a variable for systemic treatment (platinum- based version when testing *pancancer-cisplatin*; cetuximab-based version when testing *Cl3 hypoxia*) were included as covariates. The concordance index (Harrell's C-index⁵⁹) was calculated for each model to compare their discriminatory ability with the ability of models that included gene signatures (but see Hartman et al.⁶⁰ for limitations on interpreting the C-305 index). Additionally, we calculated each models measure of explained variation (R^2) as 306 defined by Royston⁶¹ and building on previous work^{62,63}. This measure is similar to R^2 of 307 linear models but was made for models analyzing censored survival data.

2.5.3. Gene signature validation models

To validate prognostic gene signatures (*172-GS* and *3 clusters HPV*), we fit Cox proportional

hazard models where we tested if the gene signature was associated with survival endpoints

while adjusting for other covariates. For each GS, we used the same endpoints and covariates

It is made available under a CC-BY-NC 4.0 International license.

as in the clinical base models, but also tested for an interaction between HPV-status and the

- GS. This allowed us to test if the same association between survival and GSs was found in
- both HPV-positive and in HPV-negative patients.
- To validate predictive gene signatures (*RSI*, *pancancer-cisplatin* and *Cl3-hypoxia*), we fit

 Cox proportional hazard models where we tested if gene signatures were associated with survival endpoints and if there was evidence that gene signatures modified the effect of the treatments (i.e., testing for an interaction between gene signatures and treatments). Finding a significant interaction where a GS is associated with survival in a specific treatment but not in others would imply that the signature is predictive. For validating each GS, we used the same covariates as in the clinical base models, but also included relevant interactions between GS and treatments. An interaction between radiotherapy and *RSI* was included when validating *RSI*. For validation of the *pancancer-cisplatin* signature, we included an interaction between the *pancancer-cisplatin* signature and systemic treatment. Similarly for validation of *Cl3-hypoxia*, we included an interaction between the *Cl3-hypoxia* signature and systemic treatment (see Appendix 3 for formulas for each GS model).

- To test the proportional hazard assumption of our Cox models, we performed sensitivity
- analyses where we fit equivalent models as described above, using 5-year survival (both for OS and DFS) as the endpoint instead of 2-year survival. We additionally estimated the
- 332 median follow-up time using the reverse Kaplan-Meier method⁶⁴.
-

3. Results

3.1. Cohort characteristics

 The largest dataset used for overall survival analyses, representing the full SuPerTreat cohort, contained patients from 6 studies, where 67% of patients were from the two largest studies [\(Table 1\)](#page-22-0). The majority of patients were men (72%) and the cohort had a median age at 339 diagnosis of 61 years (SD = 12). Most patients had loco-regionally advanced disease (85%) and underwent surgery (78%) and/or radiotherapy treatment (69%), with 42% of patients receiving systemic treatment. There was heterogeneity in tumor regions, and the most frequent primary site was oral cavity (55%) [\(Table 1\)](#page-22-0). Similar cohort characteristics were observed in the dataset used for disease-free survival [\(Table 1\)](#page-22-0), and in subsets of patients that were used to test the effect of other GSs on survival endpoints (Tables S2, S3). Among patients who received systemic treatment with information available about the therapeutic agent, 87.6% received platinum-based and 8.5% received cetuximab-based therapies (Table S3).

3.2. Gene signatures

3.2.1. Prognostic signature: *172-GS*

 The *172-GS* signature was significantly associated with 2-year OS in HPV-negative patients, where increasing the signature score by 1 (representing an increase of 1 standard deviation) resulted in 41% higher hazard (HR = 1.41 [CI: 1.25, 1.59], [Table 2,](#page-22-1) [Figure 2\)](#page-25-0). No evidence of 353 an interaction between the signature score and HPV-status was found ($p = 0.621$), indicating 354 that the association between survival and the GS was similar in HPV-positive patients (HR $=$ 1.87 [CI: 0.61, 5.78], [Table 2\)](#page-22-1). However, the score was not significantly associated with OS

It is made available under a CC-BY-NC 4.0 International license.

 in HPV-positive patients when testing the marginal effect of the signature conditioned on being HPV-positive [\(Table 2\)](#page-22-1). When fixing the signature score at zero (representing the mean score), HPV-negative patients had a 4.27-fold higher hazard than HPV-positive patients [\(Table 2\)](#page-22-1). The models C-index was 0.71 ($SE = 0.02$) and $R^2 = 0.29$. The C-index of the 360 corresponding clinical base model (i.e. not including the GS as a covariate) was 0.69 (SE = 361 0.02) and $R^2 = 0.23$.

362

363 Similar effect sizes and significance levels were found for 2-year DFS, with a significant 364 association between the signature score and survival in HPV-negative patients (HR = 1.36) 365 [CI: 1.17, 1.59], [Table 2\)](#page-22-1). There was no evidence of an interaction between the signature 366 score and HPV-status ($p = 0.651$), and the score was not significantly associated with DFS in 367 HPV-positive patients when conditioned on being HPV-positive [\(Table 2\)](#page-22-1). The models C-368 index was 0.67 (SE = 0.02) and $R^2 = 0.22$. The corresponding clinical base model had a C-369 index of 0.66 (SE = 0.02) and $R^2 = 0.18$. See Table S5 for details about other covariates 370 included in the *172-GS* models.

371

372 **3.2.2. Prognostic signature:** *3 clusters HPV*

 There was a significant association between the *3 clusters HPV* signature and 2-year OS in HPV-positive patients, where increasing the signature score resulted in a lower hazard (HR = 0.41 [CI: 0.24, 0.71], [Table 2,](#page-22-1) [Figure 3\)](#page-25-1). There was evidence of an interaction between the 376 signature score and HPV-status ($p = 0.007$), indicating that the effect of the GS was different 377 in HPV-negative patients (HR = 0.89 [CI: 0.77, 1.02], [Table 2\)](#page-22-1). Moreover, the score was not significantly associated with OS in HPV-negative patients [\(Table 2\)](#page-22-1). These patients had a 4.17-fold higher hazard than HPV-positive patients when fixing the signature score at zero [\(Table 2\)](#page-22-1). The model had a $R^2 = 0.25$ and C-index = 0.69 (SE = 0.02). The C-index of the 381 corresponding clinical base model was 0.69 (SE = 0.02) and $R^2 = 0.23$.

382

383 We found similar effect sizes and significance levels for 2-year DFS, with a significant 384 association between the GS and survival in HPV-positive patients (HR = 0.51 [CI: 0.33 , 385 0.77], [Table 2\)](#page-22-1). Evidence of an interaction between the signature score and HPV-status was 386 also found ($p = 0.001$), and the score was not significantly associated with DFS in HPV-387 negative patients [\(Table 2\)](#page-22-1). The models C-index was 0.67 (SE = 0.02) and $R^2 = 0.20$. The C-388 index of the corresponding clinical base model was 0.66 ($SE = 0.02$) and $R^2 = 0.18$. See 389 Table S6 for details about other covariates included in the *3 clusters HPV* models. 390

391 **3.2.3. Predictive signature: radiosensitivity index (***RSI***)**

392 The *RSI* was significantly associated with 2-year OS in patients receiving radiotherapy, 393 where a higher hazard was found when increasing the signature score (HR = 1.25 [CI: 1.08, 394 1.44], [Table 2,](#page-22-1) [Figure 4\)](#page-27-0). We found no evidence of an interaction between *RSI* and 395 radiotherapy (p = 0.672), suggesting that the association between survival and *RSI* was the 396 same, although not significantly associated, in patients that did not receive radiotherapy (HR 397 = 1.17 [0.90, 1.52], [Table 2,](#page-22-1) [Figure 4\)](#page-27-0). When *RSI* was set to zero, there was no significant 398 association between survival and having received radiotherapy [\(Table 2\)](#page-22-1). The models Cindex was 0.70 (SE = 0.02) and $R^2 = 0.25$. The corresponding clinical base model had a C-400 index of 0.69 (SE = 0.02) and $R^2 = 0.23$. 401

It is made available under a CC-BY-NC 4.0 International license.

402 In contrast to OS, there was no significant association between 2-year DFS and *RSI* [\(Table 2\)](#page-22-1). 403 There was also no evidence of an interaction between *RSI* and having received radiotherapy 404 (p = 0.601). The models C-index was 0.66 (SE = 0.02) and $R^2 = 0.18$. The corresponding 405 clinical base models C-index was 0.66 (SE = 0.02) and $R^2 = 0.18$. See Table S7 for details 406 about other covariates included in the *RSI* models.

407

408 **3.2.4. Predictive signature:** *Pancancer-cisplatin*

409 There was a significant association between the *pancancer-cisplatin* signature and 2-year OS 410 in patients receiving platinum-based chemotherapy, where a higher hazard was observed 411 when increasing the signature (HR = 1.29 [CI: 1.04, 1.59], [Table 2,](#page-22-1) [Figure 5\)](#page-28-0). When 412 platinum-based chemotherapy was the reference, there was no evidence of interactions 413 between the signature and systemic treatment $(p = 0.200)$ when compared to non-platinum 414 based, $p = 0.908$ when compared to no systemic therapy), suggesting that the association 415 between the signature and overall survival may be similar in these groups. However, there 416 was no significant association between survival and the signature score when conditioning on 417 receiving non-platinum based systemic therapy or when not receiving systemic treatment 418 [\(Table 2,](#page-22-1) [Figure 5\)](#page-28-0). There was also no significant association between survival and systemic 419 treatment when the signature score was set to zero [\(Table 2\)](#page-22-1). The models $R^2 = 0.32$ and C-420 index was 0.72 (SE = 0.02). The corresponding clinical base model had a C-index of 0.71 421 (SE = 0.02) and $R^2 = 0.30$.

422

423 In contrast to OS, we found no significant association between 2-year DFS and the

424 *pancancer-cisplatin* signature [\(Table 2\)](#page-22-1). There was also no evidence of interactions between

425 the score and systemic treatment when platinum-based chemotherapy was the reference ($p =$

426 0.258 when compared to non-platinum based, $p = 0.571$ when compared to no systemic

- 427 treatment). The models C-index was 0.70 (SE = 0.02) and $R^2 = 0.28$. The C-index of the 428 corresponding clinical base model was 0.70 (SE = 0.02) and $R^2 = 0.26$. See Table S8 for
- 429 details about other covariates included in the *pancancer-cisplatin* models.
- 430

431 **3.2.5. Predictive and prognostic signature:** *Cl3-hypoxia*

 The *Cl3-hypoxia* signature was significantly associated with 2-year OS in patients receiving non-cetuximab-based systemic treatments, where increasing the signature score resulted in a lower hazard (HR = 0.69 [CI: 0.54, 0.87], [Table 2,](#page-22-1) [Figure 6\)](#page-29-0). A similar, but non-significant, 435 association between OS and the GS was found for cetuximab-treated patients ($HR = 0.67$ [CI: 0.39, 1.14], [Table 2,](#page-22-1) [Figure 6\)](#page-29-0). In contrast, an opposite association was found between OS and the signature in patients who did not receive systemic treatments, where higher signature scores were associated with higher hazards (HR = 1.70 [CI: 1.12, 2.58], [Table 2,](#page-22-1) [Figure 6\)](#page-29-0). There was evidence of interactions between the signature and systemic treatment when using 440 no systemic treatment as the baseline (comparison with cetuximab group: $p = 0.006$; 441 comparison with non-cetuximab: $p < 0.001$), but no evidence of an interaction when comparing cetuximab-treated patients with patients receiving other types of systemic 443 treatment ($p = 0.919$). When the GS score was set to zero, there was no significant association between survival and systemic treatment [\(Table 2\)](#page-22-1). The models C-index was 0.73 $(SE = 0.02)$ and $R^2 = 0.34$. The C-index of the corresponding clinical base model (i.e. not 446 including the GS as a covariate) was 0.71 (SE = 0.02) and $R^2 = 0.29$. 447

It is made available under a CC-BY-NC 4.0 International license.

- Similar effect sizes and significance levels were found when analyzing 2-year DFS [\(Table 2\)](#page-22-1).
- Increasing the signature score was associated with a reduced hazard in patients receiving
- systemic treatment, while being significantly associated with an increased hazard in patients
- not receiving systemic treatments [\(Table 2\)](#page-22-1). There was evidence of interactions between the signature and systemic treatment when no systemic treatment was the baseline (comparison
- 453 with cetuximab group: $p = 0.006$; comparison with non-cetuximab: $p \le 0.001$), but no
- evidence of an interaction when comparing patients receiving cetuximab with patients
- 455 receiving non-cetuximab therapies ($p = 0.943$). The models $R^2 = 0.32$ and C-index = 0.71 (SE
- 456 = 0.02). The C-index of the corresponding clinical base model was 0.70 (SE = 0.02) and R^2 =
- 0.27. See Table S9 for details about other covariates included in the *Cl3-hypoxia GS*.
-

3.3. Sensitivity analyses

3.3.1. Coding of treatment

- We performed sensitivity analyses to evaluate the effect of using the received treatment as a proxy of intended treatment (Appendix 1). Results of these analyses are summarized below: i) All treated patients started treatment within 6 months after diagnosis, with most starting treatment within 3-4 months. In the first 6 months after diagnosis, the mortality was approximately 3%. ii) We obtained overlapping and similar treatment coefficients when comparing intended and received treatment in an external dataset with similar patients' characteristics. iii) We obtained overlapping and similar treatment coefficients when comparing received treatment with time-dependent treatment in a subset of patients where the timing of surgery was known. iv) A landmark analysis showed overlapping and similar treatment coefficients as when using received treatment. v) Quantitative bias analyses showed bias-adjusted estimates of treatment effects that overlap with estimates obtained when using received treatment.
- **3.3.2. 5-year endpoints**

 Effect sizes and significance levels from models with 5-year OS and 5-year DFS were very similar to the 2-year survival models (see Figures S4-S13 for forest plots and Tables S5-S9 for detailed results). The main difference was in the model of 5-year OS and the *Cl3-hypoxia* signature, where there was no longer evidence of an association between the score and 482 survival in patients not receiving systemic treatments (HR = 1.43 [CI: 0.96, 2.13], $p = 0.076$). Moreover, there was no longer evidence of an interaction between the score and systemic treatment when comparing patients untreated with systemic agents with patients receiving 485 cetuximab ($p = 0.068$). The median follow-up time was 1325 days (approx. 3.63 years).

4. Discussion

 In this study, we externally validated five gene signatures using one of the world's largest collections of HNSCC patients with available gene expression, harmonizing and combining

It is made available under a CC-BY-NC 4.0 International license.

 high quality clinical data from different studies. The development of this wide European dataset has shown that the integration of multisource clinical and biological databases is feasible. This successful integration is unprecedented and amplifies the knowledge about the complexity and the heterogeneity of HNSCCs, contributing to their qualification and quantification. The external validation ensures the robustness of the GSs and their potential generalizability. In addition, tumor heterogeneity and complexity coupled with the variety of treatment options imposes a biology-driven personalized approach in the curative setting of HNSCC patients. Unlike more frequent tumors (e.g., breast cancer, non-small cell lung cancer, or colorectal cancer), GSs have not been included yet either in clinical decision making, or in clinical trial eligibility and stratification of HNSCC patients. Except for the model testing associations between *RSI* and disease-free survival, all models including gene signatures outperformed their corresponding clinical omics-free base models, 503 as indicated by C-index and/or \mathbb{R}^2 . Our results confirmed two potentially prognostic signatures (*172-GS* and *3 clusters HPV*) and validated one potentially prognostic/predictive signature (*Cl3-hypoxia*) for cetuximab- and chemosensitivity. However, the results for two potentially predictive signatures (*RSI* and *pancancer-cisplatin*) were less conclusive, despite showing associations with overall survival in patients receiving radiotherapy or platinum- based chemotherapy.

510 The signature - GS^{18} was validated as a prognostic indicator for both overall and disease- free survival in patients with HPV-unrelated disease. A higher signature score is associated with a higher risk. The signature may also be prognostic in HPV-positive oropharyngeal

cancer patients, as given by the lack of evidence of an interaction between the signature and

514 HPV-status. This contrasts with previously published results¹⁹, possibly due to adjustments

for covariates and uncertainties in estimates of the signature effect for HPV-positive patients.

517 The 3 clusters HPV signature²⁰ was validated as prognostic for both OS and DFS in HPV-

518 positive oropharyngeal cancer patients, consistent with a previous validation study¹⁹.

Additionally, there was no evidence of the signature being prognostic for HPV-negative

patients, suggesting its relevance specifically to HPV-positive oropharyngeal cancer.

522 In our study, we found a link between the radiosensitivity index $(RSI)^{21}$ and overall survival

523 in patients who underwent radiotherapy, consistent with other studies^{18,19,22,65}. However, we

did not observe any interaction between *RSI* and radiotherapy. We also found a similar but

not significant association between *RSI* and OS in patients who did not receive radiotherapy.

This suggests that *RSI* may be more prognostic for survival than predictive of

radiosensitivity. This surprising finding of a prognostic effect of *RSI* in non-irradiated

patients may be because of the relatively low number of non-irradiated patients in our study.

In contrast to other studies^{22,66}, we did not find a connection between \overrightarrow{RSI} and DFS.

531 To our knowledge this is the first external validation of the *pancancer-cisplatin* signature²³ in

head and neck cancer patients. We found a negative association between the signature score

 and overall survival (OS) in patients receiving platinum-based chemotherapy. Given that higher GS scores were linked to higher cisplatin-sensitivity in the original publication²³, our

finding is in the opposite direction of what is expected. Additionally, we did not find

evidence of an interaction between systemic treatment and the signature. Due to an imbalance

in the number of patients with each type of systemic treatment, we could not draw definitive

- conclusions about the potential prognostic or predictive effects of the signature. Lastly, we
- found no associations between disease-free survival (DFS) and the *pancancer-cisplatin*

It is made available under a CC-BY-NC 4.0 International license.

 signature, suggesting that its predictive power may vary with clinical outcomes and not be universal for all cancers.

 In general, a GS is prognostic if it is able to forecast patient survival independently of the received treatment. At the same time, if a prognostic GS is tested on a subset of patients receiving curative therapies including a specific approach, then the prognostic performance necessarily implies a certain predictive capability. In this scenario, the *Cl3-hypoxia*²⁴ signature score was positively associated with both OS and DFS in patients receiving systemic treatment but negatively associated with survival in subjects not receiving systemic agents, suggesting the signature is predictive of sensitivity to systemic therapy. A similar positive association with survival endpoints was found in both cetuximab-treated patients and in patients with chemotherapy, which did not include anti-EGFR agents. The association between signature and survival is consistent with previous findings in HPV-positive 553 oropharyngeal cancer¹⁹ and in oral premalignant lesions²⁵. Previous studies have suggested that the signature is related to cetuximab-sensitivity^{26,27}, but our results indicate that it is predictive of sensitivity to systemic treatment in general.

 This study offers various opportunities for further improvement and refinement. Firstly, we used the received treatment as a proxy for intended treatment. While this breaks an assumption of the Cox regression model, we performed extensive sensitivity analyses that suggest the models are robust to this violation. Secondly, 3-7% of patients (depending on the model) were excluded for missing overall survival status or timing, and 6-19% were excluded for missing DFS. This complete case exclusion reduced the sample sizes. Still, because the 563 missingness was primarily structural⁵⁸, where the survival endpoint was missing for all patients in a study, it is unlikely that it biased the results. Third, we used the missing indicator method for missing covariates (with missingness ranging from 3-30% depending on the 566 covariate), which can lead to biased results in non-randomized studies⁶⁷, but is unlikely to result in bias unless the covariate is a strong confounder or missing in extreme proportion $(>50\% \text{ missing})^{68}$. Moreover, like the missingness in endpoints, the missingness in covariates was primarily structural, and alternative regression-based imputation methods were therefore not a viable option. Lastly, the imbalance in the number of patients with different treatments (e.g., only 35 patients received cetuximab) made it difficult to precisely estimate interactions and effects of gene signatures in small groups and made conclusions less clear.

We externally validated five gene signatures using a large integrated dataset of HNSCC

patients. Our results validated two prognostic signatures, *172-GS* and *3 clusters HPV*

signature, in HPV-negative patients and HPV-positive patients, respectively. We also

validated that the potentially predictive signatures *RSI* and *pancancer-cisplatin* were

prognostic of survival in patients with radiotherapy and platinum-based chemotherapy,

respectively, but could not conclude if these signatures are also predictive of radiosensitivity

or platinum-chemosensitivity. Lastly, we validated the *Cl3-hypoxia* signature as predictive of

- sensitivity to systemic treatment, making this signature a good candidate for use in personalized treatment decisions.
	-

584 Many clinical studies aimed at intensifying^{69–71} or de-escalating^{72–74} standard treatments have failed in head and neck oncology. A possible drawback could be the lack of an appropriate patient selection, which may have hampered the opportunity to detect a signal of clinical

benefit with a given therapeutic approach. The significant biological differences in the

current study demonstrate the high heterogeneity of HNSCCs. Therefore, future clinical trials

should pursue a better patient selection that includes a broader use of GS and incorporates

It is made available under a CC-BY-NC 4.0 International license.

them as inclusion criteria or stratification factors. In this scenario, the results of our external

- validation in one of the widest HNSCC datasets may be considered a historical benchmark for the design of future studies.
-

5. Data availability

The SuPerTreat dataset is hosted by the Services for Sensitive Data (TSD) at the University

of Oslo. Anonymized data containing only the survival endpoints and gene signature scores

 will be uploaded to Zenodo prior to publication. Access to the original data may be granted by the data owners upon application.

6. Code availability

 The underlying code (R scripts) used to analyse and validate gene signatures is available on GitHub and can be accessed via this link

- [https://github.com/erlendfossen/SuPerTreat_GS_validation.](https://github.com/erlendfossen/SuPerTreat_GS_validation)
-

7. Acknowledgements

 This work is part of the research project "Supporting Personalized Treatment Decisions in Head and Neck Cancer through Big Data (SuPerTreat)" funded within ERA PerMed JTC2019 Joint transnational call for proposals (2019) for "Personalised medicine: multidisciplinary research Toward implementation", research grant nr. ERAPERMED2019- 281 and supported by FRRB (Fondazione Regionale per la Ricerca Biomedica), BMBF (Bundesministerium für Bildung und Forschung), RCN (Norges forskningsråd), ANR (Agence nationale de la recherche) and GSRT (General Secretariat for Research and Technology). MM-S received funding from the European Union's Horizon 2020 Research and Innovation program under the Marie Skłodowska-Curie Actions Grant, agreement No. 80113 (Scientia fellowship). BD2Decide received funding from the European Union Horizon 2020 Framework Programme, Grant/Award Number: 689715. We thank the researchers, clinicians and other staff that designed and conducted the studies that this work builds on. We also thank the head and neck cancer patients that took part in the studies.

8. Author contributions

 Conceptualization: E.I.F.F., M.M.S., M.L., A.F., I.T., C.L.T., L.L, L.D.C, S.C.; Data curation: E.I.F.F., M.M.S., L.L.P, E.E.P, L.H, L.D.C, S.C.; Formal analysis: E.I.F.F., M.M.S., M.L., A.F., L.D.C, S.C.; Funding acquisition: A.F., E.H., M.F.C.U, G.F., I.T., L.L.; Investigation: I.T., V.S., K.S., C.L.T., M.K., S.T., M.P., L.L, L.D.C, S.C.; Methodology: E.I.F.F., M.M.S., M.L., A.F., L.L, L.D.C, S.C.; Resources: A.F., L.L.; Software: E.I.F.F., M.M.S.; Supervision:

M.L., A.F., M.F.C.U., G.F.; Visualization: E.I.F.F.; Writing-original draft: E.I.F.F.; Writing-

It is made available under a CC-BY-NC 4.0 International license.

 review & editing: All authors. All authors approved the submission of this manuscript. L.D.C. and S.C. contributed equally to this work as co-last authors.

9. Competing interests

M.L. reports receiving a speaker fee from MSD unrelated to the content of this work. L.L.

declares the following conflicts of interest, all unrelated to the content of this work: research

funds donated directly to the institute for clinical trials from AstraZeneca, BMS, Boehringer

 Ingelheim, Celgene International, Eisai, Exelixis, Debiopharm International SA, Hoffmann-La Roche Ltd, IRX Therapeutics, Medpace, Merck-Serono, MSD, Novartis, Pfizer, Roche,

and Buran; occasional fees for participation as a speaker at conferences/congresses or as a

scientific consultant for advisory boards from AstraZeneca, Bayer, MSD, Merck-Serono,

AccMed, Neutron Therapeutics, Inc., and Alentis. S.C. declares occasional fees for

participation as a speaker at conferences/congresses from AccMed; support for attending

meetings and/or travel from AccMed, MultiMed Engineers srl, Care Insight sas, unrelated to

the content of this work. All remaining authors declare no competing interests.

₆₄₂ References

- 1. Barsouk, A., Aluru, J. S., Rawla, P., Saginala, K. & Barsouk, A. Epidemiology, Risk Factors, and
- Prevention of Head and Neck Squamous Cell Carcinoma. *Med. Sci.* **11**, 42 (2023).
- 2. Sung, H. *et al.* Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality
- Worldwide for 36 Cancers in 185 Countries. *CA. Cancer J. Clin.* **71**, 209–249 (2021).
- 3. Gormley, M., Creaney, G., Schache, A., Ingarfield, K. & Conway, D. I. Reviewing the epidemiology
- of head and neck cancer: definitions, trends and risk factors. *Br. Dent. J.* **233**, 780–786 (2022).
- 4. Sabatini, M. E. & Chiocca, S. Human papillomavirus as a driver of head and neck cancers. *Br. J. Cancer* **122**, 306–314 (2020).
- 5. Leemans, C. R., Snijders, P. J. F. & Brakenhoff, R. H. The molecular landscape of head and neck cancer. *Nat. Rev. Cancer* **18**, 269–282 (2018).
- 6. Mes, S. W., Leemans, C. R. & Brakenhoff, R. H. Applications of molecular diagnostics for
- personalized treatment of head and neck cancer: state of the art. *Expert Rev. Mol. Diagn.* **16**, 205–221 (2016).
- 7. Reid, P. *et al.* Diversity of cancer stem cells in head and neck carcinomas: The role of HPV in
- cancer stem cell heterogeneity, plasticity and treatment response. *Radiother. Oncol.* **135**, 1–12
- (2019).
- 8. Machiels, J.-P. *et al.* Squamous cell carcinoma of the oral cavity, larynx, oropharynx and
- hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and
- follow-up. *Ann. Oncol. Off. J. Eur. Soc. Med. Oncol.* **31**, 1462–1475 (2020).
- 9. Gatta, G. *et al.* Burden and centralised treatment in Europe of rare tumours: results of
- RARECAREnet—a population-based study. *Lancet Oncol.* **18**, 1022–1039 (2017).
- 10. Ballman, K. V. Biomarker: Predictive or Prognostic? *J. Clin. Oncol.* **33**, 3968–3971 (2015).
- 11. Al-Tashi, Q. *et al.* Machine Learning Models for the Identification of Prognostic and Predictive
- Cancer Biomarkers: A Systematic Review. *Int. J. Mol. Sci.* **24**, 7781 (2023).

- 12. Huo, M. *et al.* Tumor microenvironment characterization in head and neck cancer identifies
- prognostic and immunotherapeutically relevant gene signatures. *Sci. Rep.* **10**, 11163 (2020).
- 13. Feng, B. & Hess, J. Immune-Related Mutational Landscape and Gene Signatures: Prognostic
- Value and Therapeutic Impact for Head and Neck Cancer. *Cancers* **13**, 1162 (2021).
- 14. Wang, J. *et al.* Six-gene signature for predicting survival in patients with head and neck
- squamous cell carcinoma. *Aging* **12**, 767–783 (2020).
- 15. Liu, B. *et al.* Prognostic Value of Eight-Gene Signature in Head and Neck Squamous Carcinoma.
- *Front. Oncol.* **11**, (2021).
- 16. Tonella, L., Giannoccaro, M., Alfieri, S., Canevari, S. & De Cecco, L. Gene Expression Signatures
- for Head and Neck Cancer Patient Stratification: Are Results Ready for Clinical Application? *Curr.*
- *Treat. Options Oncol.* **18**, 32 (2017).
- 17. Steckler, A. & McLeroy, K. R. The Importance of External Validity. *Am. J. Public Health* **98**, 9–10 (2008).
- 18. De Cecco, L., Bossi, P., Locati, L., Canevari, S. & Licitra, L. Comprehensive gene expression meta-
- analysis of head and neck squamous cell carcinoma microarray data defines a robust survival
- predictor. *Ann. Oncol.* **25**, 1628–1635 (2014).
- 19. Cavalieri, S. *et al.* Clinical Validity of a Prognostic Gene Expression Cluster-Based Model in
- Human Papillomavirus–Positive Oropharyngeal Carcinoma. *JCO Precis. Oncol.* 1666–1676 (2021)
- doi:10.1200/PO.21.00094.
- 20. Locati *et al.* Mining of Self-Organizing Map Gene-Expression Portraits Reveals Prognostic
- Stratification of HPV-Positive Head and Neck Squamous Cell Carcinoma. *Cancers* **11**, 1057
- (2019).
- 21. Eschrich, S. A. *et al.* A Gene Expression Model of Intrinsic Tumor Radiosensitivity: Prediction of Response and Prognosis After Chemoradiation. *Int. J. Radiat. Oncol.* **75**, 489–496 (2009).
- 22. Torres-Roca, J. F., Grass, G. D., Scott, J. G. & Eschrich, S. A. Towards Data Driven RT Prescription:
- Integrating Genomics into RT Clinical Practice. *Semin. Radiat. Oncol.* **33**, 221–231 (2023).

- 23. Wells, J. D., Griffin, J. R. & Miller, T. W. Pan-Cancer Transcriptional Models Predicting
- Chemosensitivity in Human Tumors. *Cancer Inform.* **20**, 117693512110024 (2021).
- 24. De Cecco, L. *et al.* Head and neck cancer subtypes with biological and clinical relevance: Meta-
- analysis of gene-expression data. *Oncotarget* **6**, 9627–9642 (2015).
- 25. Carenzo, A. *et al.* Gene Expression Clustering and Selected Head and Neck Cancer Gene
- Signatures Highlight Risk Probability Differences in Oral Premalignant Lesions. *Cells* **9**, 1828
- (2020).
- 26. Bossi, P. *et al.* Functional Genomics Uncover the Biology behind the Responsiveness of Head and
- Neck Squamous Cell Cancer Patients to Cetuximab. *Clin. Cancer Res.* **22**, 3961–3970 (2016).
- 27. Lenoci, D. *et al.* Biological properties of hypoxia-related gene expression models/signatures on
- clinical benefit of anti-EGFR treatment in two head and neck cancer window-of-opportunity
- trials. *Oral Oncol.* **126**, 105756 (2022).
- 28. Cavalieri, S. *et al.* Development of a multiomics database for personalized prognostic forecasting
- in head and neck cancer: The Big Data to Decide EU Project. *Head Neck* **43**, 601–612 (2021).
- 29. Sablin, M.-P. *et al.* Identification of new candidate therapeutic target genes in head and neck
- squamous cell carcinomas. *Oncotarget* **7**, 47418–47430 (2016).
- 30. Neuzillet, C. *et al.* Prognostic value of intratumoral Fusobacterium nucleatum and association
- with immune-related gene expression in oral squamous cell carcinoma patients. *Sci. Rep.* **11**,
- 7870 (2021).
- 31. Hoffmann, C. *et al.* MMP2 as an independent prognostic stratifier in oral cavity cancers.
- *Oncoimmunology* **9**, 1754094 (2020).
- 32. Leblanc, O. *et al.* Biomarkers of cetuximab resistance in patients with head and neck squamous
- cell carcinoma. *Cancer Biol. Med.* **17**, 208–217 (2020).
- 33. Lecerf, C. *et al.* Immune gene expression in head and neck squamous cell carcinoma patients.
- *Eur. J. Cancer* **121**, 210–223 (2019).

- 34. Hoffmann, C. *et al.* PD-L1 and ICOSL discriminate human Secretory and Helper dendritic cells in
- cancer, allergy and autoimmunity. *Nat. Commun.* **13**, 1983 (2022).
- 35. Moreira, A. *et al.* Prognostic value of tumor mutational burden in patients with oral cavity
- squamous cell carcinoma treated with upfront surgery. *ESMO Open* **6**, 100178 (2021).
- 36. Karabajakian, A. *et al.* Longitudinal assessment of PD-L1 expression and gene expression profiles
- in patients with head and neck cancer reveals temporal heterogeneity. *Oral Oncol.* **119**, 105368
- (2021).
- 37. The Cancer Genome Atlas (TCGA). https://www.cancer.gov/tcga.
- 38. Lawrence, M. S. *et al.* Comprehensive genomic characterization of head and neck squamous cell
- carcinomas. *Nature* **517**, 576–582 (2015).
- 39. Lohavanichbutr, P. *et al.* A 13-Gene Signature Prognostic of HPV-Negative OSCC: Discovery and
- External Validation. *Clin. Cancer Res.* **19**, 1197–1203 (2013).
- 40. Brazma, A. *et al.* Minimum information about a microarray experiment (MIAME)—toward standards for microarray data. *Nat. Genet.* **29**, 365–371 (2001).
- 41. Brazma, A. *et al.* MINSEQE: Minimum Information about a high-throughput Nucleotide
- SeQuencing Experiment a proposal for standards in functional genomic data reporting. (2012)
- doi:10.5281/zenodo.5706412.
- 42. Edge, S. B. & Compton, C. C. The American Joint Committee on Cancer: the 7th Edition of the
- AJCC Cancer Staging Manual and the Future of TNM. *Ann. Surg. Oncol.* **17**, 1471–1474 (2010).
- 43. Hernández, L. *et al.* HeNeCOn: An ontology for integrative research in Head and Neck cancer.
- *Int. J. Med. Inf.* **181**, 105284 (2024).
- 44. Nauta, I. H. *et al.* The unveiled reality of human papillomavirus as risk factor for oral cavity
- squamous cell carcinoma. *Int. J. Cancer* **149**, 420–430 (2021).
- 45. Jones, M. & Fowler, R. Immortal time bias in observational studies of time-to-event outcomes. *J.*
- *Crit. Care* **36**, 195–199 (2016).

- 46. Ness, A. R. *et al.* Establishing a large prospective clinical cohort in people with head and neck
- cancer as a biomedical resource: head and neck 5000. *BMC Cancer* **14**, 973 (2014).
- 47. Ness, A. R. *et al.* Recruitment, response rates and characteristics of 5511 people enrolled in a
- prospective clinical cohort study: head and neck 5000. *Clin. Otolaryngol.* **41**, 804–809 (2016).
- 48. Mi, X., Hammill, B. G., Curtis, L. H., Lai, E. C.-C. & Setoguchi, S. Use of the landmark method to
- address immortal person-time bias in comparative effectiveness research: a simulation study.
- *Stat. Med.* **35**, 4824–4836 (2016).
- 49. Gleiss, A., Oberbauer, R. & Heinze, G. An unjustified benefit: immortal time bias in the analysis of time-dependent events. *Transpl. Int.* **31**, 125–130 (2018).
- 50. Lash, T. L., Fink, A. K. & Fox, M. P. Misclassification. in *Applying Quantitative Bias Analysis to*
- *Epidemiologic Data* (eds. Lash, T. L., Fox, M. P. & Fink, A. K.) 79–108 (Springer, New York, NY,
- 2009). doi:10.1007/978-0-387-87959-8_6.
- 51. Ritchie, M. E. *et al.* limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res.* **43**, e47 (2015).
- 52. Langfelder, P. & Horvath, S. WGCNA: an R package for weighted correlation network analysis.
- *BMC Bioinformatics* **9**, 559 (2008).
- 53. Johnson, W. E., Li, C. & Rabinovic, A. Adjusting batch effects in microarray expression data using
- empirical Bayes methods. *Biostatistics* **8**, 118–127 (2007).
- 54. Zhang, Y., Jenkins, D. F., Manimaran, S. & Johnson, W. E. Alternative empirical Bayes models for adjusting for batch effects in genomic studies. *BMC Bioinformatics* **19**, 262 (2018).
- 55. Nygaard, V., Rødland, E. A. & Hovig, E. Methods that remove batch effects while retaining group
- differences may lead to exaggerated confidence in downstream analyses. *Biostatistics* **17**, 29–39
- (2016).
- 56. Carenzo, A. *et al.* hacksig: a unified and tidy R framework to easily compute gene expression
- signature scores. *Bioinformatics* **38**, 2940–2942 (2022).

- 57. R Core Team. *R: A Language and Environment for Statistical Computing*. (R Foundation for
- Statistical Computing, Vienna, Austria, 2022).
- 58. Mitra, R. *et al.* Learning from data with structured missingness. *Nat. Mach. Intell.* **5**, 13–23
- (2023).
- 59. Harrell, F. E., Jr, Califf, R. M., Pryor, D. B., Lee, K. L. & Rosati, R. A. Evaluating the Yield of Medical
- Tests. *JAMA* **247**, 2543–2546 (1982).
- 60. Hartman, N., Kim, S., He, K. & Kalbfleisch, J. D. Pitfalls of the concordance index for survival
- outcomes. *Stat. Med.* **42**, 2179–2190 (2023).
- 61. Royston, P. Explained Variation for Survival Models. *Stata J.* **6**, 83–96 (2006).
- 62. O'Quigley, J., Xu, R. & Stare, J. Explained randomness in proportional hazards models. *Stat. Med.*
- **24**, 479–489 (2005).
- 63. Nagelkerke, N. J. D. A note on a general definition of the coefficient of determination.
- *Biometrika* **78**, 691–692 (1991).
- 64. Shuster, J. J. Median follow-up in clinical trials. *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* **9**, 191–
- 192 (1991).
- 65. Dai, Y.-H. *et al.* Radiosensitivity index emerges as a potential biomarker for combined
- radiotherapy and immunotherapy. *Npj Genomic Med.* **6**, 40 (2021).
- 66. Torres-Roca, J. F. A molecular assay of tumor radiosensitivity: a roadmap towards biology-based
- personalized radiation therapy. *Pers. Med.* **9**, 547–557 (2012).
- 67. Groenwold, R. H. H. *et al.* Missing covariate data in clinical research: when and when not to use
- the missing-indicator method for analysis. *CMAJ* **184**, 1265–1269 (2012).
- 68. Song, M., Zhou, X., Pazaris, M. & Spiegelman, D. The Missing Covariate Indicator Method is
- Nearly Valid Almost Always. Preprint at https://doi.org/10.48550/arXiv.2111.00138 (2021).
- 69. Merck. Merck Provides Update on Xevinapant Program in Locally Advanced Head and Neck
- Cancer [Press release]. https://www.merckgroup.com/en/news/xevinapant-update.html (2024).

It is made available under a CC-BY-NC 4.0 International license. perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.09.24.24314278;](https://doi.org/10.1101/2024.09.24.24314278) this version posted September 24, 2024. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has grant

- alone in patients with locally advanced squamous cell carcinoma of the head and neck: a
- randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. *Lancet Oncol.* **22**, 450–
- 462 (2021).
- 71. Machiels, J.-P. *et al.* Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus
- concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of
- the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial. *Lancet Oncol.* **25**,

572–587 (2024).

- 72. Mehanna, H. *et al.* Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-
- positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase
- 3 trial. *The Lancet* **393**, 51–60 (2019).
- 73. Gillison, M. L. *et al.* Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive
- oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority

trial. *The Lancet* **393**, 40–50 (2019).

- 74. Tao, Y. *et al.* Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with
- locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01
- PembroRad): a multicenter, randomized, phase II trial. *Ann. Oncol.* **34**, 101–110 (2023).

It is made available under a CC-BY-NC 4.0 International license.

812 **Table 1.** Cohort characteristics for head and neck cancer patients used to test the *172-GS* and *3* 813 *clusters HPV* signatures. The disease-free survival (DFS) dataset is a subset of the overall survival

814 dataset, where patients without data on DFS are excluded.

815

It is made available under a CC-BY-NC 4.0 International license.

817 Table 2. Hazard ratios (HR) of gene signatures and covariates that were tested in interaction

818 with the signatures for head and neck cancer patients. Estimates are from models where 2-

819 year overall survival or 2-year disease-free survival was the endpoint and the effect of other

820 clinical covariates were jointly estimated (see Tables S5, S6, S7, S8, S9 for detailed results).

It is made available under a CC-BY-NC 4.0 International license.

Figure 1. Exclusion flowchart. The largest number of eligible patients used in the most

 inclusive models (models testing the signatures *172-GS*, *3 clusters HPV* and *RSI* with overall survival as the endpoint) is shown. See Figures S1, S2, S3 for exclusion flowcharts for other gene signature models.

- **survival**. **a, b** Estimated relationship in HPV-positive patients and HPV-negative patients, respectively. The signature score is scaled to a mean of 0 and a standard deviation of 1. Note
- the difference in sample size (N) per group. **c, d** Distribution of signature values in HPV-
- positive and HPV-negative patients, respectively.
-
-
-
-

overall survival. **a, b** Estimated relationship in HPV-positive patients and HPV-negative

patients, respectively. The signature score is scaled to a mean of 0 and a standard deviation of

1. Note the difference in sample size (N) per group. **c, d** Distribution of signature values in

HPV-positive and HPV-negative patients, respectively.

It is made available under a CC-BY-NC 4.0 International license. perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.09.24.24314278;](https://doi.org/10.1101/2024.09.24.24314278) this version posted September 24, 2024. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has grant

Figure 4. Estimated relationship between the radiosensitivity index (*RSI***) and 2-year**

 overall survival. **a** Relationship in patients that did not receive radiotherapy. **b** Relationship in patients that received radiotherapy. **c** Relationship in patients with missing information

about radiotherapy treatment. The *RSI* score is scaled to a mean of 0 and a standard deviation

of 1. Note the difference in sample size (N) per group.

It is made available under a CC-BY-NC 4.0 International license.

857
858

 Figure 5. Estimated relationship between the *pancancer-cisplatin* **signature and 2-year overall survival**. **a** Relationship in patients that received platinum-based chemotherapy. **b** Relationship in patients that received non-platinum based systemic treatment. **c** Relationship in patients that did not receive systemic treatment. **d** Relationship in patients with missing information about systemic treatment. The signature score is scaled to a mean of 0 and a

standard deviation of 1. Note the difference in sample size (N) per group.

It is made available under a CC-BY-NC 4.0 International license.

866
867 **Figure 6. Estimated relationship between the** *Cl3***-***hypoxia* **signature and 2-year overall**

survival. **a** Relationship in patients that received cetuximab-based treatment. **b** Relationship

in patients that received non-cetuximab based systemic treatment. **c** Relationship in patients

that did not receive systemic treatment. **d** Relationship in patients with missing information

about systemic treatment. The signature score is scaled to a mean of 0 and a standard

deviation of 1. Note the difference in sample size (N) per group.